Lucid Diligence Brief - BioPharma

BioMarin’s $475M Fabry Disease Licensing Deal | Lucid Diligence Brief

This Lucid Diligence Brief explores BioMarin’s expansion of its Fabry disease…


Rare Disease news

Rare Diseases Today—May 21, 2026

This week’s Rare Diseases update highlights regulatory progress, orphan…


Cell_Gene_Therapy

Cell and Gene Therapy Today—February 26, 2026

This week's Cell and Gene therapy update highlights regulatory momentum,…


Cell and Gene Therapy Clinical Trials lansdcape 2023 Edition.

Cell and Gene Therapy Clinical Trials – 2024 Edition 

Gene therapy clinical trials promise transformative breakthroughs in treating…


Privacy Preference Center